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P < .001). Prior chemotherapy, lymphoid malignancies,
longer interval fromdiagnosis toHCT, andpositiveCMVstatus
were also associated with LOS, with a trend towards signiﬁ-
cance (P ¼ .06 for all). In multivariable, logistic regression
analyses, poor PS (OR 1.31 per 10 point decrease,P ¼ .031),
unrelateddonor (OR3.14 P< .001), cord blood transplantation
(OR 2.42, P¼ .048), CMVpositivity of either donor or recipient
(OR 1.91, P¼ .018), and CD34+ cell dose (OR 1.35 per 1x106/kg
decrease, P < .001) were signiﬁcantly associated with pro-
longed LOS. 5-year non-relapse mortality (NRM) for pts
hospitalized 6 wks was signiﬁcantly worse than for pts
hospitalized<6 wks (60.2% vs. 31.8%, P< .001), as was overall
survival (OS) at 5 years, (16.6% vs. 42.8%, P< .001). Therewere
no differences in the incidence or degree of acute GVHD.
In conclusion, hospitalization 6 wks following HCT is
associated with signiﬁcantly worse NRM and OS. Poor PS,
CMV positivity, decreased CD34+ cell dose, and unrelated
and cord blood transplants have previously been identiﬁed
as factors predictive of poor outcome and are also factors that
contribute to prolonged LOS. Efforts should be made to
optimize modiﬁable factors such as cell dose in HCT pts,
especially those with other risk factors, such as having an
unrelated or cord blood donor.363
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Purpose: Late-onset hemorrhagic cystitis (LOHC) is
a common complication following allogeneic hematopoietic
stem cell transplantation (allo-HSCT), which was mainly
associated with BK virus and adenovirus (ADV). However,
there still some patients developed LOHC without infection
of BKV and ADV. Several retrospective studies showed that
CMV infection was associated with LOHC. So, we design this
prospective study to deﬁne the relationship between CMV
infection and LOHC.
Design and Methods: Fifty consecutive patients who
received allo-HSCT between October 2011 and December
2011 were prospectively investigated to screen BKV, ADV and
CMV in the urine and plasma using Real-time Polymerase
Chain Reaction (RT-PCR).Results: Twenty-one out of the 50 patients developed LOHC
with a cumulative incidence of 42%7.1%.The median time
from transplantation to onset of LOHC was 29 (range, 4-64)
days. There are 34 patients and 21 patients developed CMV
viremia and CMV viruria, respectively, within day 100. The
cumulative incidence of LOHC in patients with CMV viremia
was signiﬁcantly higher than those without CMV viremia
(58.8% vs. 6.3%, P ¼ .001) on day 100 after transplantation.
Patients with CMV viruria had a signiﬁcant higher cumula-
tive incidence of LOHC than those without CMV viruria
(60.7% vs. 18.2%, P ¼ .006). The cumulative incidence of CMV
viremia and CMV viruria in patients with LOHC (n¼21)
versus those without LOHC (n¼29) were 95.2% vs. 48.3% (P ¼
.001) and 80.9% vs. 34.5% (P ¼ .001), respectively. The
cumulative incidence of LOHC in patients whose plasma BKV
load increased more than or equal to 103-fold over baseline
was signiﬁcantly higher than those with plasma load
increase less than 103-fold (67.9%9.2%vs. 9.1%6.3%, P <
.001). The cumulative incidence of LOHC in patients whose
urine BKV load increased more than or equal to 104-fold over
baseline was signiﬁcantly higher than those with urine load
increase less than 104-fold (66.7% 10.3% vs. 19.2%7.9%, P ¼
.002). ADV was positive in 4 patients including one patient
with LOHC. Multivirariate analysis showed that CMV viremia
(HR¼10.496, 95% CI: 1.527-86.570, P ¼ .018) and plasma BKV
load increased more than or equal to 103-fold compared to
baseline level (HR¼10.669, 95% CI: 2.452-46.419, P ¼ .002)
were two independent risk factors for LOHC.
Conclusion: Our data suggest that CMV viremia is a risk
factor for LOHC following allo-HSCT.364
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Objective: Plasma ADAMTS13 may play a role in the patho-
genesis of hematopoietic stem-cell transplantation (HSCT)
related thrombosis by cleaving the prothrombotic ultralarge
VWF into less active VWF. This study was to investigate the
alterations of ADAMTS13 and VWF in HSCT recipients during
transplantation, and to evaluate their signiﬁcance in trans-
plantation-related thrombotic complications.
Methods: Plasma ADAMTS13 activity was detected by ﬂuo-
rescence resonance energy transfer substrate VWF73
(FRETS-VWF73) assay in 113 hematologic patients receiving
allogeneic-HSCT. Of all the patients recruited for his study, 8
patients were diagnosed to have the thrombotic disorders
and 49 patients were classiﬁed to have acute graft-versus-
host disease (aGVHD). The alterations of ADAMTS13 activity
and VWF level in the plasma of patients were analyzed
during transplantation, and the correlation between
ADAMTS13/VWF and transplantation-related thrombosis
was evaluated using the SAS program (version 9.3).
Results: The average plasma ADAMTS13 activity in 113 cases
following HSCT at each period were less than the healthy
controls (P< .01), while the VWF antigen level in each period
were higher than the controls (P < .05). Among all the
patients after pretreatment, 69 showed decreased plasma
ADAMTS13 activities (59.3%), including 9 patients with more
than 60% (8.0%) decrease, while the average plasma VWF
antigen level of this 69 patients was signiﬁcantly increased in
patients after pretreatment (P< .05). Considering thrombotic
complications, the data showed that 8 patients with
